BioSpace News Archive

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the closing of its upsized initial public offering of 7,539,400 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 983,400 additional shares of common stock, at a public offering price of $25.00 per share

Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.

Pulmonx Corporation, a global leader in minimally invasive treatments for severe lung disease, announced that Blue Cross Blue Shield Michigan and Horizon BCBS have issued positive coverage policies for endobronchial valves, such as the Zephyr® Endobronchial Valve, for severe emphysema, a form of COPD.

Hancock Jaffe Laboratories, Inc., a medical device company focused on improving the standard of care in the treatment of venous disease, announced a corporate update which includes a planned corporate rebranding and strategic prioritization of the Company’s development pipeline.

Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding debt securities.

Vaxart, Inc., announced that it has formed a Manufacturing and Quality Advisory Board.

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Puma Biotechnology, Inc. announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:00 a.m. EDT on Tuesday, September 28, at the 2021 Cantor Virtual Global Healthcare Conference.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™

On World Alzheimer’s Day, Missouri leaders and economic development officials praise C₂N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease.